Department of Pediatrics, Division of Critical Care, UC Davis School of Medicine, UC Davis Children's Hospital, Sacramento, CA.
Department of Medicine, Cardiovascular Research Institute, UCSF, San Francisco, CA.
Crit Care Med. 2022 May 1;50(5):837-847. doi: 10.1097/CCM.0000000000005373. Epub 2021 Oct 25.
Soluble receptor for advanced glycation end products is a known plasma marker of alveolar epithelial injury. However, RAGE is also expressed on cell types beyond the lung, and its activation leads to up-regulation of pro-inflammatory mediators. We sought to examine the relationship between plasma soluble receptor for advanced glycation end products and primary pulmonary dysfunction, extrapulmonary organ dysfunction, and mortality in pediatric acute respiratory distress syndrome patients at two early time points following acute respiratory distress syndrome diagnosis and compare these results to plasma surfactant protein-D, a marker of pure alveolar epithelial injury.
Prospective observational study.
Five academic PICUs.
Two hundred fifty-eight pediatric patients 30 days to 18 years old meeting Berlin Criteria for acute respiratory distress syndrome.
None.
Plasma was collected for soluble receptor for advanced glycation end products and surfactant protein-D measurements within 24 hours (day 1) and 48 to 72 hours (day 3) after acute respiratory distress syndrome diagnosis. Similar to surfactant protein-D, plasma soluble receptor for advanced glycation end products was associated with a higher oxygenation index (p < 0.01) and worse lung injury score (p < 0.001) at the time of acute respiratory distress syndrome diagnosis. However, unlike surfactant protein-D, plasma soluble receptor for advanced glycation end products was associated with worse extrapulmonary Pediatric Logistic Organ Dysfunction score during ICU stay (day 3; p < 0.01) and positively correlated with plasma levels of interleukin-6 (p < 0.01), tumor necrosis factor-α (p < 0.01), and angiopoietin-2 (p < 0.01). Among children with indirect lung injury, plasma soluble receptor for advanced glycation end products was associated with mortality independent of age, sex, race, cancer/bone marrow transplant, and Pediatric Risk of Mortality score (day 3; odds ratio, 3.14; 95% CI, 1.46-6.75; p < 0.01).
Unlike surfactant protein-D, which is primarily localized to the alveolar epithelium plasma soluble receptor for advanced glycation end products is systemically expressed and correlates with markers of inflammation, extrapulmonary multiple organ dysfunction, and death in pediatric acute respiratory distress syndrome with indirect lung injury. This suggests that unlike surfactant protein-D, soluble receptor for advanced glycation end products is a multifaceted marker of alveolar injury and increased inflammation and that receptor for advanced glycation end products activation may contribute to the pathogenesis of multiple organ failure among children with indirect acute respiratory distress syndrome.
晚期糖基化终产物受体是一种已知的肺泡上皮损伤的血浆标志物。然而,RAGE 也在肺以外的细胞类型上表达,其激活导致促炎介质的上调。我们试图研究在急性呼吸窘迫综合征诊断后两个早期时间点,血浆可溶性晚期糖基化终产物受体与原发性肺功能障碍、肺外器官功能障碍和儿科急性呼吸窘迫综合征患者死亡率之间的关系,并将这些结果与表面活性剂蛋白-D 进行比较,后者是纯肺泡上皮损伤的标志物。
前瞻性观察性研究。
五所学术性儿科重症监护病房。
符合柏林急性呼吸窘迫综合征标准的 30 天至 18 岁的 258 名儿科患者。
无。
在急性呼吸窘迫综合征诊断后 24 小时(第 1 天)和 48 至 72 小时(第 3 天)内采集血浆,用于可溶性晚期糖基化终产物受体和表面活性剂蛋白-D 测量。与表面活性剂蛋白-D 相似,可溶性晚期糖基化终产物受体在急性呼吸窘迫综合征诊断时与更高的氧合指数(p < 0.01)和更差的肺损伤评分(p < 0.001)相关。然而,与表面活性剂蛋白-D 不同,可溶性晚期糖基化终产物受体与 ICU 期间更差的肺外儿科逻辑器官功能障碍评分相关(第 3 天;p < 0.01),并与白细胞介素-6(p < 0.01)、肿瘤坏死因子-α(p < 0.01)和血管生成素-2(p < 0.01)的血浆水平呈正相关。在间接性肺损伤的儿童中,可溶性晚期糖基化终产物受体与死亡率相关,而与年龄、性别、种族、癌症/骨髓移植和儿科死亡率评分无关(第 3 天;优势比,3.14;95%CI,1.46-6.75;p < 0.01)。
与主要定位于肺泡上皮的表面活性剂蛋白-D 不同,可溶性晚期糖基化终产物受体在全身表达,并与炎症、肺外多器官功能障碍和有间接性肺损伤的儿科急性呼吸窘迫综合征的死亡标志物相关。这表明,与表面活性剂蛋白-D 不同,可溶性晚期糖基化终产物受体是肺泡损伤和炎症增加的多方面标志物,受体的激活可能导致儿童间接性急性呼吸窘迫综合征多器官衰竭的发病机制。